Aerobic Fitness, Mitochondrial Function, and Fatty Liver Disease.

有氧健身、线粒体功能和脂肪肝。

基本信息

  • 批准号:
    10205054
  • 负责人:
  • 金额:
    $ 46.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-07-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

Low aerobic capacity (AC) is a powerful predictor of early mortality and risk for metabolic disease including excessive hepatic fat storage (steatosis). Conversely, high AC is clinically associated with protection against hepatic steatosis and a healthier, longer lifespan even in the face of obesity. We will utilize a rat model selectively bred for divergent intrinsic AC (high or low running capacity [HCR/LCR]) to unravel mechanisms by which AC impacts hepatic steatosis and metabolic pathologies. In a sedentary condition, HCR rats have a 40% higher intrinsic AC and are protected against high fat/sucrose (HFD)-induced hepatic steatosis and insulin resistance while LCR are highly susceptible. We have shown that differences in hepatic mitochondrial function (MitoFX: defined here as fat oxidation, and respiratory capacity) between the HCR and LCR play an important role in their protection or susceptibility for hepatic steatosis, respectively. New data suggests that hepatic metabolic flux through TCA cycle and gluconeogenesis are also elevated in the HCR over the LCR rat, but these pathways have yet to be examined in the context of protection against steatosis. In addition, novel preliminary data suggests HCR rats have elevated bile acid (BA) synthesis paired with increased fecal sterol and BA excretion compared to LCR. Exercise trained mice which also have elevated MitoFX and are protected from steatosis show evidence of a similar upregulation of BA synthesis and excretion. We will test the hypothesis that increases in hepatic BA synthesis and fecal excretion is critical to the high AC and chronic exercise phenotype(s) and contributes to hepatic MitoFx, metabolic flux, and protection of steatosis by: 1) Pulling acetyl-CoA out of the mitochondria (minimizing feedback inhibition and mitochondrial protein acetylation) and 2) diverting acetyl-CoA away from accumulation and de-novo-lipogenesis (DNL) and towards BA synthesis and subsequent fecal loss via a “siphoning mechanism”. We will test these mechanisms utilizing pharmacological and molecular tools to modulate CYP7a1 activity and BA synthesis combined with in-vivo metabolic tracers in HCR/LCR rats and exercise vs. sedentary mice. Additionally, HCR livers display greater metabolic and transcriptional adaptability in response to high-fat diet (HFD) feeding than LCR. Our preliminary data suggests that enhanced transcriptional adaptability in the HCR livers is caused by increases in the acetylation of histones (H3K9ac and H3K27ac) that coordinate expression of genes involved in mitochondrial metabolism and specifically for BA synthesis. Thus, we posit that high AC and exercise induced increases in metabolic flux and enhanced BA synthesis likely increase acetyl CoA flux out of the mitochondria and into the cytosol where it can serve as a substrate for histone acetylation. This proposal will also test the hypothesis that livers from HCR rats and from exercised mice can transcriptionally adapt to high fat diets and avoid steatosis through a relationship linking hepatic MitoFX, BA synthesis and excretion, and epigenetic mechanisms (histone acetylation).
有氧能力 (AC) 低是早期死亡率和代谢疾病风险的有力预测因素,包括肝脂肪储存过多(脂肪变性)。相反,高 AC 在临床上与预防肝脂肪变性和更健康、更长的寿命有关,即使在肥胖的情况下也是如此。我们将利用针对不同的内在 AC(高或低运行能力 [HCR/LCR])选择性培育的大鼠模型来揭示 AC 影响肝脂肪变性和代谢病理的机制。在久坐的情况下,HCR 大鼠的内在 AC 升高 40%,并且可以免受高脂肪/蔗糖 (HFD) 诱导的肝脂肪变性和胰岛素抵抗,而 LCR 则高度敏感。我们已经表明,HCR 和 LCR 之间的肝线粒体功能(MitoFX:此处定义为脂肪氧化和呼吸能力)的差异分别在其保护肝脂肪变性或对肝脂肪变性的易感性方面发挥着重要作用。新数据表明,与 LCR 大鼠相比,HCR 中通过 TCA 循环和糖异生的肝脏代谢通量也有所升高,但这些途径尚未在防止脂肪变性的背景下进行检查。此外,新的初步数据表明,与 LCR 相比,HCR 大鼠的胆汁酸 (BA) 合成增加,同时粪便甾醇和 BA 排泄增加。经过运动训练的小鼠 MitoFX 也有所升高,并且免受脂肪变性,显示出类似的 BA 合成和排泄上调的证据。我们将检验以下假设:肝脏 BA 合成和粪便排泄的增加对于高 AC 和慢性运动表型至关重要,并通过以下方式促进肝脏 MitoFx、代谢通量和脂肪变性保护:1) 将乙酰辅酶A 从线粒体中拉出(最大限度地减少反馈抑制和线粒体蛋白乙酰化)和 2) 转移 乙酰辅酶A远离积累和从头脂肪生成(DNL),并通过“虹吸机制”促进BA合成和随后的粪便损失。我们将利用药理学和分子工具调节 CYP7a1 活性和 BA 合成,并结合 HCR/LCR 大鼠和运动小鼠与久坐小鼠的体内代谢示踪剂来测试这些机制。此外,与 LCR 相比,HCR 肝脏对高脂饮食 (HFD) 喂养表现出更强的代谢和转录适应性。我们的初步数据表明,HCR 肝脏中转录适应性的增强是由组蛋白(H3K9ac 和 H3K27ac)乙酰化的增加引起的,这些组蛋白协调参与线粒体代谢(特别是 BA 合成)的基因表达。因此,我们认为高 AC 和运动诱导的代谢通量增加和 BA 合成增强可能会增加乙酰辅酶 A 流出线粒体并进入细胞质的通量,在细胞质中它可以作为组蛋白乙酰化的底物。该提案还将检验以下假设:HCR 大鼠和运动小鼠的肝脏可以通过肝脏 MitoFX、BA 合成和排泄以及表观遗传机制(组蛋白乙酰化)之间的关系,在转录上适应高脂肪饮食并避免脂肪变性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John P Thyfault其他文献

John P Thyfault的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John P Thyfault', 18)}}的其他基金

Kansas Center for Metabolism and Obesity REsearch (KC-MORE)
堪萨斯代谢和肥胖研究中心 (KC-MORE)
  • 批准号:
    10725916
  • 财政年份:
    2022
  • 资助金额:
    $ 46.6万
  • 项目类别:
Kansas Center for Metabolism and Obesity REsearch (KC-MORE)
堪萨斯代谢和肥胖研究中心 (KC-MORE)
  • 批准号:
    10598012
  • 财政年份:
    2022
  • 资助金额:
    $ 46.6万
  • 项目类别:
Kansas Center for Metabolism and Obesity REsearch (KC-MORE)
堪萨斯代谢和肥胖研究中心 (KC-MORE)
  • 批准号:
    10799329
  • 财政年份:
    2022
  • 资助金额:
    $ 46.6万
  • 项目类别:
Translating Obesity, Metabolic Dysfunction and Comorbid Disease States
转化肥胖、代谢功能障碍和共存疾病状态
  • 批准号:
    10411630
  • 财政年份:
    2022
  • 资助金额:
    $ 46.6万
  • 项目类别:
Translating Obesity, Metabolic Dysfunction and Comorbid Disease States
转化肥胖、代谢功能障碍和共存疾病状态
  • 批准号:
    10623307
  • 财政年份:
    2022
  • 资助金额:
    $ 46.6万
  • 项目类别:
Divergence in Aerobic Capacity Drives Liver and Brain Health
有氧能力的差异促进肝脏和大脑健康
  • 批准号:
    10286535
  • 财政年份:
    2019
  • 资助金额:
    $ 46.6万
  • 项目类别:
Aerobic Fitness, Mitochondrial Function, and Fatty Liver Disease.
有氧健身、线粒体功能和脂肪肝。
  • 批准号:
    10442514
  • 财政年份:
    2019
  • 资助金额:
    $ 46.6万
  • 项目类别:
Skeletal muscle mitochondrial abnormalities in Alzheimer's Disease
阿尔茨海默病中的骨骼肌线粒体异常
  • 批准号:
    9474088
  • 财政年份:
    2017
  • 资助金额:
    $ 46.6万
  • 项目类别:
Skeletal muscle mitochondrial abnormalities in Alzheimer's Disease
阿尔茨海默病中的骨骼肌线粒体异常
  • 批准号:
    9322823
  • 财政年份:
    2017
  • 资助金额:
    $ 46.6万
  • 项目类别:
Sexual dimorphism, hepatic mitochondrial adaptations, and hepatic steatosis
性别二态性、肝线粒体适应和肝脂肪变性
  • 批准号:
    9891404
  • 财政年份:
    2014
  • 资助金额:
    $ 46.6万
  • 项目类别:

相似海外基金

Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
  • 批准号:
    EP/Y000331/1
  • 财政年份:
    2023
  • 资助金额:
    $ 46.6万
  • 项目类别:
    Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
  • 批准号:
    10677295
  • 财政年份:
    2023
  • 资助金额:
    $ 46.6万
  • 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
  • 批准号:
    10635599
  • 财政年份:
    2023
  • 资助金额:
    $ 46.6万
  • 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
  • 批准号:
    10752320
  • 财政年份:
    2023
  • 资助金额:
    $ 46.6万
  • 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
  • 批准号:
    478927
  • 财政年份:
    2023
  • 资助金额:
    $ 46.6万
  • 项目类别:
    Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
  • 批准号:
    10855703
  • 财政年份:
    2023
  • 资助金额:
    $ 46.6万
  • 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
  • 批准号:
    10654210
  • 财政年份:
    2023
  • 资助金额:
    $ 46.6万
  • 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
  • 批准号:
    10733915
  • 财政年份:
    2023
  • 资助金额:
    $ 46.6万
  • 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
  • 批准号:
    10667952
  • 财政年份:
    2023
  • 资助金额:
    $ 46.6万
  • 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
  • 批准号:
    10726986
  • 财政年份:
    2023
  • 资助金额:
    $ 46.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了